Ser392 phosphorylation regulates the oncogenic function of mutant p53

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4749-4754

  Yap, Damian B S ^a   Hsieh, Jung Kuang ^a   Zhong, Shan ^a   Heath, Vicky ^b   Gusterson, Barry ^b   Crook, Tim ^a   Lu, Xin ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CISPLATIN; GLUTAMIC ACID; HISTIDINE; MUTANT PROTEIN; PROTEIN P53; SERINE; TRYPTOPHAN; ANTINEOPLASTIC AGENT;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST TUMOR; CARCINOGENESIS; CELL TRANSFORMATION; CYTOTOXICITY; DNA DAMAGE; DOMINANT NEGATIVE MUTANT; DRUG RESISTANCE; EMBRYO; EMBRYO CELL; FIBROBLAST; HUMAN; HUMAN CELL; MUTANT; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RAT; ULTRAVIOLET IRRADIATION; ANIMAL; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MUTATION; OSTEOSARCOMA; PHOSPHORYLATION; PHYSIOLOGY; TRANSACTIVATION; TUMOR CELL LINE; ULTRAVIOLET RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; OSTEOSARCOMA; PHOSPHORYLATION; RATS; SERINE; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 3142685265     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-1305-2     Document Type: Article

References (39)

1. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancer. Science (Wash DC) 1991;253:49-53.
2. Crook T, Marston NJ, Sara EA, Vousden KH. Transcription activation by p53 correlates with suppression of growth but not transformation. Cell 1994;79:817-27.
3. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 1993;7:2565-74.
4. Pavletich N, Chambers K, Pabo CO. The DNA-binding domain of p53 contains the four conserved region and the major mutation hot spots. Genes Dev 1993;7:2556-64.
5. Cho Y, Gorina S, Jeffery PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Wash DC) 1994;265:346-55.
6. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
7. Lu X, Lane DP. Different induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993;75: 765-78.
8. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984;4:1689-94.
9. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilisation of human p53 in response to DNA damage. Proc Natl Acad Sci USA 1999;96:13777-82.
10. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 1992;12:5041-9.
11. Sakaguchi K, Saito S, Higashimoto Y, et al. Damage-mediated phosphorylation of human p53 theonine 18 through a cascade mediated by a casein-1 like kinase effect on mdm2 binding. J Biol Chem 2000;275:9278-83.
12. Shieh S-Y, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by mdm2. Cell 1997;91:325-34.
13. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995;83:237-45.
14. 1 cyclin-dependent kinases. Nature (Lond) 1995;376:88-91.
15. Minamoto T, Bushmann T, Habelhah H, et al. Distinct pattern of p53 phosphorylation in human tumours. Oncogene 2001;20:3341-7.
16. Blaydes JP, Hupp TR. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene 1998;17:1045-52.
17. Siliciano JD, Canman CE, Taya Y, et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997;11:3471-81.
18. Keller DM, Zeng X, Wang Y, et al. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell 2001;7:283-92.
19. Meek DW, Simon S, Kikkawa U, Eckhart W. The p53 tumour suppressor protein is phsophorylated at serine 389 by casein kinase II. EMBO J 1990;9:3253-60.
20. Lu H, Taya Y, Ikeda M, Levine AJ. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at semine-392. Proc Natl Acad Sci USA 1998;95:6399-402.
21. Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV not gamma radiation. Proc Natl Acad Sci USA 1998;95:2834-7.
22. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992;71:875-86.
23. Fuchs B, O'Connor D, Fallis L, Sheidtmann KH, Lu X. p53 phosphorylation mutants retain transcription activity. Oncogene 1995;10:789-93.
24. Ashcroft M, Kubbutat MHG, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 1999:19:1751-8.
25. Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ, Herrlich P. DNA damage induced p53 stabilization: no indication for an involvment of p53 phosphorylation. Oncogene 1999;18:1723-32.
26. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
27. Yap DB, Hsieh JK, Lu X. mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation. J Biol Chem 2000;275:37296-302.
28. O'Connor DJ, Lam EW-F, Griffin S, et al. Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO 1995;14:6184-92.
29. Hsieh J-K, Chan FSG, O'Connor DJ, et al. Rb regulates the stability and the apoptotic function of p53 via mdm2. Mol Cell 1999;3:181-93.
30. Hsieh J-K, Fredersdorf S, Kauzarides T, Martin K, Lu X. E2F1 induced apoptosis requires DNA binding but not transcriptional activity and is inhibited by the retino-blastoma protein through direct interaction. Genes Dev 1997;11:1840-52.
31. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8.
32. Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989;63:739-46.
33. Di Como CJ, Gaiddon C, Prives C. P73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438-49.
34. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature (Lond) 2000;407:777-83.
35. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85.
36. Selivanova G, Iotsova V, Okan I, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997;3:632-8.
37. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond) 1992;356:215-21.
38. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature (Lond) 2000; 404:99-103.
39. Meek DW. Mechanisms of switching on p53: a role for covalent modification? Oncogene 1999;18:7666-75.